Selenium Yeast
ApprovedSmall molecule
Selenium Yeast is one of 17 small molecule programs targeting Differentiated Thyroid Carcinoma. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Differentiated Thyroid Carcinoma
#DrugCompanyPhaseTrials
1Tafinlar
NovartisPhase 3
Mekinist
NovartisPhase 3
Anlotinib Hydrochloride
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Approved
Cabometyx
Bristol-Myers SquibbPhase 2
Cotellic
RochePhase 2
Lenvima
EisaiPhase 2
AL2846
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 2
Adriamycin
GGynecologic Oncology Group
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Selenium Yeast. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- QQianfoshan Hospital